A phase II, randomized trial using the small molecule tyrosine kinase inhibitor lapatinib as a first-line treatment in patients with FISH positive advanced or metastatic breast cancer

Henry Gómez, G. W. Sledge, Dinesh Chandra Doval et al.|Journal of Clinical Oncology|2005

Cited by 72